Patients
14.2 % of people
People aged 65 and over, Singapore, 2025 (WHO).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Chandani Patel
Singapore NAD+ Supplements Market Industry Trends and Forecast to 2034: Segmented by (Ingredient, Form, Distribution Channel, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.5 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $0.8 Mn | — | — |
| 2025 (base) | $0.9 Mn | +$0.1 Mn | — |
| 2026 (forecast) | $1.0 Mn | +$0.1 Mn | +11.7% |
| 2027 (forecast) | $1.1 Mn | +$0.1 Mn | +24.8% |
| 2028 (forecast) | $1.2 Mn | +$0.1 Mn | +39.4% |
| 2029 (forecast) | $1.4 Mn | +$0.1 Mn | +55.7% |
| 2030 (forecast) | $1.5 Mn | +$0.2 Mn | +73.9% |
| 2031 (forecast) | $1.7 Mn | +$0.2 Mn | +94.2% |
| 2032 (forecast) | $1.9 Mn | +$0.2 Mn | +117% |
| 2033 (forecast) | $2.1 Mn | +$0.2 Mn | +142.3% |
| 2034 (forecast) | $2.4 Mn | +$0.2 Mn | +170.7% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $0.9 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $2.4 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 11.7% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | Nicotinamide Adenine Dinucleotide (NAD+) Supplements |
| Segments | Ingredient, form and distribution channel (see all) |
| Key players | ChromaDex, Elysium Health, Thorne, Life Extension, Renue By Science (see all) |
| Regulator in Singapore | HSASource: Health Sciences Authority. Checked 14 Nov 2026.Source: Health Sciences Authority. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
NAD+ supplements, such as NMN and nicotinamide riboside, aim to raise levels of NAD+, a molecule linked to cell energy that falls with age.
Key segments of the NAD+ Supplements market include ingredient (Nicotinamide Riboside, NMN and NAD+ Direct) and form (Capsules, Powders and IV and Injections).
An ageing population, longer life expectancy, rising interest in healthy ageing and new science on how the body ages are driving the NAD+ Supplements market. Older adults and their families are spending more on staying active and independent.
Preventive care, personalised plans based on biomarkers and home-based services give the NAD+ Supplements market room to grow, especially in fast-ageing countries in Asia and Europe.
Limited clinical proof for some longevity products, high out-of-pocket costs, regulation that does not treat ageing as a disease and uneven access hold back the NAD+ Supplements market.
The NAD+ Supplements market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Therapeutic products need registration with the Health Sciences Authority (HSA).[1] Health supplements do not need approval from the Health Sciences Authority (HSA) before sale, but must not contain banned or harmful ingredients.[1] People aged 65 and over: 14.2% of people in 2025, the latest WHO figure for Singapore.[2]
[1] Health Sciences Authority. Checked 14 Nov 2026.
[2] WHO Global Health Observatory, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
Food and supplement rules, labelling and health-claim regulations govern NAD+ Supplements products. Authorities such as the US FDA, EFSA and national food safety bodies set what can be sold and claimed in Singapore.
What doctors and scientists are doing in NAD+ Supplements right now, from free public sources.
14.2 % of people
People aged 65 and over, Singapore, 2025 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
From our blog
Singapore · 2 shared keywords
Singapore · 2 shared keywords
Singapore · 2 shared keywords
Singapore · 2 shared keywords
Singapore · 2 shared keywords
Singapore · 2 shared keywords
Healthcare Services · Singapore
Digital Health · Singapore
Pharmaceuticals · Singapore
Medical Devices · Singapore
Medical Devices · Singapore
Medical Devices · Singapore